OK, I can understand your position for 50/50 since you essentially discount the PDD and Rett results to zero relevance to AD. To put it another way, you just don't believe 2-73 has any likelihood of being a platform drug, and the Anavex MOA theory is, to an investor, worthless.
Market Data 
Markets 
AI
